Erratum: Pharmacokinetics and pharmacodynamics of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease (American Journal of Physiology - Renal Physiology (2020) 319 (F84-F92) DOI: 10.1152/ajprenal.00603.2019)

Pharmacokinetics and pharmacodynamics of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease. Am J Physiol Renal Physiol 319: F84-F92, 2020. First published July 6, 2020. doi: 10.1152/ajprenal.00603.2019. In the original article, a statement regarding the development of TTI-101 was missing from the Induction of CKD in rats and treatment with TTI-101 section of the MATERIALS AND METHODS. The necessary information has been added to the revised text shown below. In addition, there was an error in the DISCLOSURES statement. The revised disclosure statement is also shown below. MATERIALS AND METHODS Induction of CKD in rats and treatment with TTI-101. TTI-101 (formerly C1889) is a small molecule, direct Stat3 inhibitor developed by D. J. Tweardy’s group in collaboration with Tvardi Therapeutics (Houston, TX). TTI-101 was formulated for oral dosing by dissolving it in a mixture of Food and Drug Administration-approved oral excipients (Labrasol: 60% and PEG-400: 40%). Briefly, 500 mg TTI-101 was mixed with 7.5 mL Labrasol followed by 1 min of sonication. Five milliliters of PEG-400 were then added to the mixture followed by 5 min of sonication. The final concentration of TTI-101 was 40 mg/mL. DISCLOSURES D.J.T is a cofounder of Tvardi. In addition, D.J.T. receives compensation as a member of Tvardi Therapeutics’ scientific advisory board and also holds equity in the company. None of the other authors has any conflicts of interest, financial or otherwise, to disclose.